Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    100%(3 trials)

    Phase Distribution

    Phase 1
    1
    33%
    Phase 3
    2
    67%

    Phase Distribution

    1

    Early Stage

    0

    Mid Stage

    2

    Late Stage

    Phase Distribution3 total trials
    Phase 1Safety & dosage
    1(33.3%)
    Phase 3Large-scale testing
    2(66.7%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(3)

    Detailed Status

    Completed3

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 11 (33.3%)
    Phase 32 (66.7%)

    Trials by Status

    completed3100%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_3

    A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

    NCT02271217
    completedphase_1

    Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

    NCT01468350
    completedphase_3

    Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

    NCT01328379

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT02271217Phase 3

    A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

    Completed
    NCT01468350Phase 1

    Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy

    Completed
    NCT01328379Phase 3

    Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3